IDYA - IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events

PR Newswire

SAN FRANCISCO , March 4, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor relations events.

Leerink Partners Global Biopharma Conference
Monday, March 11 ^th , 2024 at 12:40 PM ET
• Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Andrew Berens , M.D., Senior Managing Director, Targeted Oncology

Jefferies Biotech on the Bay Summit
Tuesday, March 12 ^th , 2024 at 8:00 AM ET
• Panel: "Novel Targeted-Oncology: Approaches, Advancements, & Future Directions", with participation by Yujiro S. Hata, Chief Executive Officer, hosted by Maury Raycroft , Ph.D. Equity Research Analyst, Biotechnology

A live audio webcast of conference events, as permitted by conference host, will be available at the "Investors/News and Events/Investor Calendar" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host.  A replay of available webcasts will be accessible for 30 days following the live event.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.  IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies.  IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's recent Annual Report on Form 10-K filed on February 20, 2024 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.

Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio. com

SOURCE IDEAYA Biosciences, Inc.